SCHEMBL874946

SCHEMBL874946

Cc1ccc2nnn(CCC(C(=O)O)S(=O)(=O)c3ccc(NC(=O)c4ccc(F)cc4)cc3)c(=O)c2c1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 9/20 0.43
TCF7L2 Q9NQB0 9/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
GPR139 Q6DWJ6 4/20 0.42
MMP2 P08253 1/20 0.40
MMP9 P14780 1/20 0.40
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
TP53 P04637 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
THRB P10828 1/20 0.39
PKM P14618 1/20 0.39
BLM P54132 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CTDSP1 Q9GZU7 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL875092 0.95 GPR139 (0.44) MEN1KMT2AGPR139MMP2MMP9
SCHEMBL874269 0.92 CTNNB1 (0.43) CTNNB1TCF7L2MEN1KMT2AGPR139
SCHEMBL875236 0.91 MAPT (0.45) CTNNB1TCF7L2MEN1KMT2AGPR139
SCHEMBL874966 0.91 GPR139 (0.49) MEN1KMT2AGPR139MMP2MMP9
SCHEMBL878389 0.89 CTNNB1 (0.45) CTNNB1TCF7L2GPR139POLBHTT
SCHEMBL875318 0.89 KMT2A (0.46) MEN1KMT2AGPR139MMP2MMP9
SCHEMBL874819 0.89 GPR139 (0.44) MEN1KMT2AGPR139MMP2MMP9
SCHEMBL877309 0.88 MMP2 (0.51) GPR139MMP2MMP9POLB
SCHEMBL875435 0.88 GPR139 (0.49) GPR139MMP2MMP9KDM4EALDH1A1
SCHEMBL874410 0.87 HTT (0.54) MEN1KMT2AGPR139MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140148459-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2014-05-29 US claimed
US-20140148459-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2014-05-29 US disclosed
EP-2619185-A1 MATRIX METALLOPROTEINASE INHIBITORS Ranbaxy Laboratories Limited (IN) 2013-07-31 EP disclosed
WO-2012038942-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140148459-A1 MATRIX METALLOPROTEINASE INHIBITORS MMP9, MMP12, MMP10 CTNNB1 2748/4885TCF7L2 3550/4885MEN1 1755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.